Transaction DateRecipientSharesTypePriceValue
23rd September 2020Partners L P/Il Bvf7,201Open or private purchase$18.20$131,056.76
23rd September 2020Partners L P/Il Bvf9,888Open or private purchase$18.20$179,959.62
22nd September 2020Partners L P/Il Bvf6,960Open or private purchase$18.45$128,382.07
22nd September 2020Partners L P/Il Bvf4,991Open or private purchase$18.45$92,062.49
22nd September 2020Partners L P/Il Bvf32Open or private purchase$3.80$121.56
21st September 2020Partners L P/Il Bvf10,069Open or private purchase$18.39$185,119.57
21st September 2020Partners L P/Il Bvf12,259Open or private purchase$18.39$225,382.94
15th September 2020Partners L P/Il Bvf77,751Open or private purchase$11.75$913,574.25
15th September 2020Partners L P/Il Bvf10,258Open or private purchase$11.75$120,531.50
15th September 2020Partners L P/Il Bvf58,745Open or private purchase$11.75$690,253.75
Pieris Pharmaceuticals
Pieris Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas.


Ticker: PIRS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1583648
Employees: 127
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $44 M (-28%)
Assets, Current: $92 M (-19%)
Property, Plant and Equipment, Net: $21 M (0%)
Other Assets, Noncurrent: $2 M (-37%)
Assets: $118 M (-16%)
Accounts Payable, Current: $4 M (-24%)
Accrued Liabilities, Current: $6 M (-40%)
Liabilities, Current: $18 M (-32%)
Liabilities: $71 M (-20%)
Common Stock, Value, Issued: $52 Th (-5%)
Common Stock, Shares, Issued: $52 M (-5%)
Additional Paid in Capital, Common Stock: $230 M (1%)
Retained Earnings (Accumulated Deficit): $183 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-46%)
Stockholders' Equity (Parent): $47 M (0%)
Liabilities and Equity: $118 M (-16%)
Research and Development: $11 M (-52%)
General and Administrative Expenses: $5 M (-48%)
Operating Income/Loss: $5 M (-45%)